Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$18B
P/E ratio
n/m (loss)
Div yield
3.1%
EPS (TTM)
-$0.26
Revenue
$14.3B
Rev. growth
-3%
Free cash flow
$2.2B
Patients/yr
~1B
In plain English
Viatris is one of the world's largest medicine factories you've never heard of: a generics-and-brands giant born in 2020 when Mylan merged with Pfizer's old Upjohn unit. It makes the off-patent and branded pills — Lipitor, Viagra, Lyrica, Norvasc, EpiPen, antiretrovirals and thousands more — that reach roughly a billion patients a year, and is now slimming down (selling its Biocon biosimilars stake) to fund a pivot toward higher-margin novel and complex drugs.
In simple terms
What Viatris really sells
Viatris is one of the world's largest medicine factories you've never heard of: a generics-and-brands giant born in 2020 when Mylan merged with Pfizer's old Upjohn unit. It makes the off-patent and branded pills — Lipitor, Viagra, Lyrica, Norvasc, EpiPen, antiretrovirals and thousands more — that reach roughly a billion patients a year, and is now slimming down (selling its Biocon biosimilars stake) to fund a pivot toward higher-margin novel and complex drugs.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.